eloralintide vs tirzepatide Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight Eloralintide, a selective amylin receptor
Pay in 4 interest-free payments of $7.23 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
02155-5/asset/fbf43461-d7e3-4b2b-9776-9027045a3823/main.assets/gr1_lrg.jpg)

























